You are currently viewing the abstract.
View Full TextLog in to view the full text
AAAS login provides access to Science for AAAS members, and access to other journals in the Science family to users who have purchased individual subscriptions.
More options
Download and print this article for your personal scholarly, research, and educational use.
Buy a single issue of Science for just $15 USD.
Abstract
Classical, ligand-activated genomic effects of estrogen receptors (ERs) were once thought to mediate all estrogen responses. It is now accepted that rapid, nongenomic responses, mediated by ER-containing membrane complexes, occur in many tissues. The endothelium is a major target of such responses and is the critical regulatory tissue that, when normally functional, determines a state of "vascular health." When dysfunctional, the phenotypic and functional alterations result in vascular pathology, the most common form of which is atherosclerosis. Nitric oxide (NO) is a vascular protective substance generated by endothelial NO synthase (eNOS) in endothelial cells. The engagement of membrane ERs by 17β-estradiol (E2) is a potent stimulus to eNOS activation and NO release. Here, we describe the multimolecular components of ER-containing membrane complex assembly and the mechanisms directing ER targeting to caveolae microdomains in the plasma membrane. We discuss the possibility that various ERα splice forms, expressed in endothelial cells, may be particularly efficient signal transducers and may use classical receptor domains for membrane targeting and insertion. Finally, we discuss the biomedical ramifications of ER-mediated endothelial activation, including the controversies surrounding hormone replacement therapy and cardiovascular disease.
